Salute e Benessere

Bio X Cell Unveils New Brand Identity, Reinforcing Global Leadership in…

Bio X Cell's refreshed look marks the company's deepened commitment to modern research across biopharma, academia, and biotech. As the only life science solutions provider able to support researchers with 100% PhD level technical support and the only functional antibody company able to claim nearly 30,000 product citations, the refreshed branding, logo, and branded typeface represent the evolution of Bio X Cell's place alongside scientific advancement from classic in vivo models to advanced…
PR Newswire
14/10/2025

Codis Launches as Global CDMO for Commercial Spray Drying and Amorphous Solid…

With facilities in St. Louis, MO, Seymour, IN and Haverhill, UK, Codis offers: With facilities inSt. Louis, MO,Seymour, INand Haverhill, UK, Codis offers: "Codis is built on a foundation of scale, quality, and global reach," saidNicolas Fortin, Codis CEO. "With a total of40,000 m2of manufacturing space, three GMP facilities and with 7 of regulatory approvals achieved, we are uniquely positioned to help pharmaceutical innovators accelerate therapies from development to market...
PR Newswire
14/10/2025

Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations…

Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his discovery of the Arctic mutation in Alzheimer's disease. Eisai is responsible for the clinical development, applications for market approval and commercialization of Leqembi for Alzheimer's disease. BioArctic has the right to commercialize Leqembi in the Nordic region together with Eisai and the two…
PR Newswire
14/10/2025

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best…

TOKYO and CAMBRIDGE, Mass., Oct.13, 2025(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that LEQEMBI ®IQLIK™, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer’s disease (AD) has been selected by TIME as one of the “Best Inventions of 2025” in the Medical and Healthcare...
Nasdaq GlobeNewswire
14/10/2025

NABR Comment on IUCN Determination

A separate petition filed with the IUCN by Dr. Hank Jenkins asserts that the Hansen et al. authors possess conflicts of interest that require further investigation by the IUCN. It is unclear if such conflicts exist, or if the authors of the IUCN review possess conflicts requiring disclosure or recusal. A separate petition filed with the IUCN by Dr.Hank Jenkinsasserts that the Hansen et al. authors possess conflicts of interest that require further investigation by the IUCN. It is unclear if...
PR Newswire
14/10/2025

Allergic Rhino-Conjunctivitis Market Poised for Significant Growth in the Coming…

Allergic Rhino-Conjunctivitis Market Summary Allergic Rhino-Conjunctivitis Market Summary Discover the allergic rhino-conjunctivitis new treatment @New Treatments for Allergic Rhino-Conjunctivitis Key Factors Driving the Growth of the Allergic Rhino-Conjunctivitis Market Rising Prevalence of Allergic Conditions The global incidence of allergic rhinitis and conjunctivitis is on the rise, influenced by factors such as increased pollution, urbanization, and environmental allergens...
PR Newswire
13/10/2025

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an…

Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and non-small cell lung cancer.Data from the Phase 1 trial of ZW191 provide readthrough to Zymeworks’ broader ADC portfolio utilizing its novel bystander active topoisomerase-1 inhibitor payload, ZD06519.VANCOUVER, British Columbia, Oct.13, 2025(GLOBE NEWSWIRE) -- Zymeworks Inc...
Nasdaq GlobeNewswire
13/10/2025

According to S&P Global Ratings, MAXIMA GRUPĖ UAB plans to divest its businesses…

On October 10, 2025, the international credit rating agency S&P Global Ratings assessed the planned changes at MAXIMA GRUPĖ. Following the review, MAXIMA GRUPĖ‘s BB+ credit rating with a stable outlook remained unchanged. In its review, S&P Global Ratings notes that the planned separation of MAXIMA GRUPĖ operations in Poland and Bulgaria will reduce the group's size, geographical diversification, and growth prospects. At the same time, the separation will allow the transfer of…
Nasdaq GlobeNewswire
13/10/2025

Cosmos Health Purchases an Additional $300,000 in Ethereum Under Its $300…

Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has purchased an additional $300,000 worth of Ethereum (ETH), increasing its total investment in ETH to $1.8 million.This latest purchase was made under Cosmos Health’s previously announced $300 million digital assets facility, which supports the Company’s ongoing strategy to diversify its portfolio through strategic digital...
Nasdaq GlobeNewswire
13/10/2025

Oxurion signs letter of intent for the contemplated acquisition of a CRO with…

Leuven, BELGIUM, October 13, 2025, 6:30 PM – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company based in Leuven, announces the signing of a letter of intent (LOI) to acquire a majority stake in a French Contract Research Organization (CRO) specialized in clinical development and regulatory affairs…
Actusnews Wire
13/10/2025

Oxurion ondertekent intentieverklaring voor de voorgenomen overname van een CRO…

Leuven, BELGIË, 13 oktober 2025, 18u30 – Oxurion NV (Euronext Brussel: OXUR) kondigt vandaag de ondertekening aan van een intentieverklaring (Letter of Intent, LOI) met het oog op de overname van een meerderheidsbelang in een Franse Contract Research Organization (CRO), gespecialiseerd in klinische ontwikkeling en regelgevende aangelegenheden…
Actusnews Wire
13/10/2025

Press release: Transparency Notification from Shareholder

Transparency Notification from ShareholderGhent, Belgium – 13 October 2025 – Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification in relation to the entity listed below, notifying the number of voting rights attached to the shares mentioned next to its name in the table below…
Nasdaq GlobeNewswire
13/10/2025

Nanomedicine Market Size to Reach US$ 389.52 Billion by 2033, Driven by…

AI Revolutionizes Nanomedicine Market by Enhancing Drug Design, Precision Delivery, and Personalized Treatments AI Revolutionizes Nanomedicine Market by Enhancing Drug Design, Precision Delivery, and Personalized Treatments Artificial intelligence (AI) is revolutionizing the nanomedicine market by enabling the design of nanomedicines with precise therapeutic effects. AI and machine learning predict key drug properties, optimizing efficiency and safety. Advanced AI-based sensors allow...
PR Newswire
13/10/2025

Cardiovascular Drugs Market Size to Reach US$ 247.8 Billion by 2033, Driven by…

Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/cardiovascular-therapeutic-drugs-market Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/cardiovascular-therapeutic-drugs-market Browse in-depth TOC on 'Cardiovascular Drugs Market' 53 – Tables 49 – Figures 180 – Pages ...
PR Newswire
13/10/2025

Aortic Endografts Market to Reach $6.2 billion, Globally, by 2034 at 6.3% CAGR…

Market Introduction Market Introduction Aortic endografts are minimally invasive medical devices used for the endovascular repair of aortic aneurysms, particularly abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA). These grafts are deployed through catheter-based techniques, eliminating the need for open surgery and offering reduced perioperative risks, shorter recovery time, and improved patient outcomes. The aortic endografts market is gaining momentum due to rise in...
PR Newswire
13/10/2025

Blood Gas Analyzer Market worth US$3.38 billion by 2030 with 4.6% CAGR |…

Browse in-depth TOC on "Blood Gas Analyzer Market" Browse in-depth TOC on "Blood Gas Analyzer Market" 216 - Tables 50 - Figures 306 - Pages By sample type,the blood gas analyzer market is segmented based on sample type into arterial, venous, and capillary blood. In 2024, the arterial blood segment held the largest share of the market, as it provides the most accurate and reliable measurement of oxygen, carbon dioxide, and pH levels, which are critical for patient…
PR Newswire
13/10/2025

Omega-3 Supplements Market Size Set to Reach US$ 17.08 Billion by 2032, Driven…

Market Dynamics & Growth Drivers Market Dynamics & Growth Drivers Preventive Healthcare Trend:Consumers are proactively managing heart health, brain function, inflammation, and immunity, driving strong demand for omega-3 supplements known for their clinically proven benefits. Clinical Validation & Regulatory Support:Multiple clinical studies linking EPA and DHA with cardiovascular, neurological, and eye health have strengthened physician recommendations and consumer trust,...
PR Newswire
13/10/2025

Global Electric Actuator Market Growth Accelerates Amid Rising Adoption in Water…

The global Electric Actuator Market revenue was USD 2549 Million in 2022 and is forecast to a readjusted size of USD 3297.1 Million by 2029 with a CAGR of 3.7% during the forecast period (2023-2029). The global Electric Actuator Market revenue wasUSD 2549 Millionin 2022 and is forecast to a readjusted size ofUSD 3297.1 Millionby 2029 with a CAGR of 3.7% during the forecast period (2023-2029). Get Free Sample Report on Electric Actuator Market What are the key factors...
PR Newswire
13/10/2025

Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the…

"Waters continues to make strategic investments in large molecules, recognizing that advanced tools for bioanalytical characterization play a critical role in driving therapeutic breakthroughs. Today, we are proud to introduce the first-of-its-kind Xevo Charge Detection Mass Spectrometer, enabling the precise analysis of previously unmeasurable molecules," said Udit Batra, Ph.D., President and Chief Executive Officer, Waters Corporation. "We believe the Xevo CDMS will accelerate…
PR Newswire
13/10/2025

Evaxion to present a breadth of data from phase 2 trial with AI-designed…

Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17, 2025, followed by a webinar on October 22, 2025, providing further insights into the clinical findings COPENHAGEN, Denmark, October 13, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present a wide range of data from its phase 2 trial with lead...
Nasdaq GlobeNewswire
13/10/2025

Thousand Oaks Biologics Shanghai ADC Site receives EU QP Declaration

Throughout the audit, the inspection team recognized Thousand Oaks Biologics Shanghai's state-of-the-art facilities, stringent quality management systems, and highly skilled technical team, concluding that the site meets EU GMP requirements. Throughout the audit, the inspection team recognized Thousand Oaks Biologics Shanghai's state-of-the-art facilities, stringent quality management systems, and highly skilled technical team, concluding that the site meets EU GMP requirements. Since its...
PR Newswire
13/10/2025

Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings

- VCN-01 expanded mPDAC data from VIRAGE Phase 2b trial to be presented at ESMO 2025 -- SYN-004 Interim blinded safety and pharmacokinetic data to be presented at IDWeek 2025 - Rockville, Md., Oct.13, 2025(GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced upcoming presentations at the European...
Nasdaq GlobeNewswire
13/10/2025

Fundus Camera Market Insights: Segmentation by Type and Technology

Transparency Market Research
13/10/2025

Scintillator Market to Reach $643 million by 2024 in short term and $1,062.5…

Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A08822 Download Sample Pages of Research Overview:https://www.alliedmarketresearch.com/request-sample/A08822 Prime determinants of growth The scintillator market is primarily driven by rising applications in medical imaging, homeland security, and nuclear safety, as scintillators enable accurate radiation detection and high-quality imaging. However, high production costs and limited...
PR Newswire
13/10/2025
Altri  Comunicati